pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Undisclosed · news · pharmadog
← back to Undisclosed
News mentioning Undisclosed
68
stories
2d
Foghorn cuts 40% of workforce
biospace
3d
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
fiercebiotech
5d
Beam sues 2 biotechs, alleging theft of base editing trade secrets
biopharma dive
6d
Precision Neuroscience taps $250M in Series D funding for brain-computer interface
fiercebiotech
6d
6 immunology targets to sustain a mammoth I&I market
biospace
10d
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
biospace
10d
Growth mode: 3 biotechs that are staffing up after series B raises
biospace
11d
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
11d
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
biospace
19d
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
19d
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
19d
Newly formed Jaguar acquires Afib device assets from J&J
fiercebiotech
20d
Judge blocks Trump administration plans to limit visa length for grad students, postdocs
stat
24d
Encoded raises $275M series F for Dravet syndrome gene therapy
biospace
24d
August biopharma layoffs impact just over 500, down 90% year over year
biospace
25d
Encoded closes $275M Series F for Dravet syndrome drug
endpoints
25d
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
biospace
25d
GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturing
fiercebiotech
26d
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
26d
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
fiercebiotech
26d
BrainChild Bio targets deadly pediatric brain cancer with $116M series A
biospace
Sep 3, 26
The pediatricians who take in vaccine-skeptical parents others won’t
stat
Sep 1, 26
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T
biospace
Aug 31, 26
STAT+: Trump strikes nine more deals with drugmakers to lower prices
stat
Aug 31, 26
Lilly adds to immune drug pipeline with $2.9B Merida buyout
biopharma dive
Aug 28, 26
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
biospace
Aug 21, 26
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
biospace
Aug 20, 26
Lilly pens deal with Gateway Labs resident Amplitude for RNA vaccine platform for infectious disease
fiercebiotech
Aug 18, 26
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
biospace
Aug 17, 26
Slate, Fulcrum to combine in reverse merger
biopharma dive
← prev
page 1 of 3
next →
